GlassScriptPhysician profile
Jay David Walls
NPI 1821093956
$3,604.89
in general payments reported to CMS, 2019-2025
32 companies · $547 in 2025
The $547 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $61.72 · 2021: $355 · 2022: $376 · 2023: $1,412 · 2024: $854 · 2025: $547.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,525 · Education: $288.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,524.86 |
| Education | $287.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $410.45 | 2019-2024 | Xarelto |
| Incyte Corporation | $353.71 | 2022-2023 | Jakafi, Monjuvi, Pemazyre |
| Janssen Scientific Affairs, LLC | $329.35 | 2021-2023 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $304.65 | 2023-2025 | Andexxa, Calquence, Enhertu |
| E.R. Squibb & Sons, L.L.C. | $299.20 | 2023-2025 | Eliquis, Reblozyl, Opdivo |
| Gilead Sciences, INC. | $246.96 | 2023-2025 | Trodelvy |
| Novartis Pharmaceuticals Corporation | $229.58 | 2023-2025 | |
| Seagen INC. | $196.49 | 2023 | Adcetris, Tukysa |
| Epizyme, INC. | $121.42 | 2021 | |
| Lilly USA, LLC | $103.27 | 2023-2025 | Verzenio, Jaypirca, Retevmo |
| Bayer Healthcare Pharmaceuticals INC. | $102.92 | 2023-2025 | |
| Celgene Corporation | $88.29 | 2023-2025 | Reblozyl, Pomalyst |
| G1 Therapeutics, INC. | $83.85 | 2022 | |
| Amgen INC. | $73.50 | 2022-2023 | Kyprolis, Blincyto, Lumakras |
| Karyopharm Therapeutics INC. | $70.55 | 2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blueprint Medicines Corporation | $69.75 | 2023 | Ayvakit |
| Pfizer INC. | $68.82 | 2024 | |
| Daiichi Sankyo INC. | $51.71 | 2023-2024 | Enhertu |
| Merck Sharp & Dohme LLC | $49.47 | 2024 | Keytruda, Welireg, Lynparza |
| Janssen Biotech, INC. | $44.54 | 2023-2025 | Darzalex, Tecvayli, Imbruvica |
| Eisai INC. | $41.62 | 2023-2025 | |
| Pharmaessentia USA Corporation | $39.05 | 2025 | Besremi |
| Array Biopharma INC | $37.87 | 2024-2025 | Mektovi, Lorbrena, Braftovi |
| Pharmacosmos Therapeutics INC. | $30.93 | 2023 | Monoferric |
| Csl Behring | $24.85 | 2024 | Hemgenix |
| Alexion Pharmaceuticals, INC. | $21.29 | 2024 | Ultomiris |
| Azurity Pharmaceuticals, INC. | $20.88 | 2025 | Danziten |
| Stemline Therapeutics INC. | $19.12 | 2023 | Orserdu |
| Foundation Medicine, INC. | $18.84 | 2023 | |
| Kyowa Kirin, INC. | $18.29 | 2025 | |
| Kite Pharma, INC. | $17.44 | 2023 | |
| Shield Therapeutics INC | $16.23 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Walls listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.